cor2ed
engage checkpoint medical linkedin twitter
bg

Publication Snapshot: Regorafenib for the Treatment of Sarcoma

Publication Snapshot: Regorafenib for the Treatment of Sarcoma

Video snapshot, slide set and infographic available

Video snapshot, slide set and infographic available

Prof. Robert Maki

The review paper, Regorafenib for the Treatment of Sarcoma, was recently published in Current Treatment Options in Oncology, 23 (11):1477-1502 (2022).

We are pleased to share a snapshot of the paper in this video from Prof. Robert Maki, along with accompanying slides and an infographic summary of the findings.

Physicians face challenges in selecting the most appropriate and effective treatments for sarcomas. In this paper, experts summarise the unmet needs of this patient group and review the current trial data to examine the safety profile and clinical activity of regorafenib in sarcoma subtypes.

 

Clinical takeaways:

  • Regorafenib demonstrated benefit in patients with osteosarcoma, Ewing sarcoma and non-adipocytic soft tissue sarcomas who had progressed on prior therapy
  • Patients who have otherwise limited treatment options may benefit from regorafenib therapy
Portrait of Robert Maki
Prof. Robert Maki

Medical Oncology

Univeristy of Pennsylvania

United States (US)

preview next

Regorafenib for the Treatment of Sarcoma

time Key Publication Snapshot | open 4 min | Dec 2022

I agree that this educational programme:

This educational programme is supported by an Independent Medical Education Grant from Bayer

SARCOMA CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.

Other programmes of interest

Other programmes developed by Prof. Robert Maki